NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free SURF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0950-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43Volume1.51 million shsAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Surface Oncology alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Surface Oncology Stock (NASDAQ:SURF)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details SURF Stock News HeadlinesMay 3, 2024 | msn.comNewly discovered mechanism of T-cell control can interfere with cancer immunotherapiesMay 1, 2024 | finance.yahoo.comValar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder CancerMay 5, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.May 1, 2024 | bloomberg.comUK’s FTSE 100 Edges Lower in Thin Trading Ahead of Fed DecisionMay 1, 2024 | msn.comNew technique improves T cell-based immunotherapies for solid tumorsMay 1, 2024 | msn.comIncyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call TranscriptMay 1, 2024 | msn.comScientists Debunk 'Really Dangerous' Online Myths About Sun ProtectionMay 1, 2024 | finance.yahoo.comCD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity InsightMay 5, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.May 1, 2024 | msn.comScientists Debunk 'Really Dangerous' Myths About Sun ProtectionApril 30, 2024 | msn.comNew guidelines shape the future of neuroendocrine tumor managementApril 29, 2024 | forbes.comAdvanced Stage Colorectal Cancer In Young Adults Is A Growing CrisisApril 29, 2024 | usnews.comKing Charles Returns to Duties After Cancer TreatmentApril 28, 2024 | msn.comOn a whim, Emma decided to donate plasma. Then she got a phone call.April 27, 2024 | msn.comBiomarkers identified for successful treatment of bone marrow tumorsApril 25, 2024 | tmcnet.comMedigene presents streamlined 6-day, high stemness TCR-T therapy production processApril 24, 2024 | msn.comCAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in clinical trialApril 24, 2024 | markets.businessinsider.comBuy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and FibrosisApril 24, 2024 | yahoo.comPalomar Health introduces new cancer imaging machines in San DiegoApril 23, 2024 | msn.comFDA approves immunotherapy drug combo for non-muscle invasive bladder cancerApril 18, 2024 | msn.comMill Creek clinic can now cure some skin cancers without surgeryApril 18, 2024 | finance.yahoo.comPathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into ClinicApril 17, 2024 | msn.comGritstone bio (GRTS) Price Target Decreased by 37.04% to 5.78April 17, 2024 | msn.comTargeted therapies outperform hundreds of other drugs in 'priming' lung cancer cells for destructionApril 16, 2024 | finance.yahoo.comCompass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsApril 11, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual MeetingApril 10, 2024 | msn.comLook Up and See the FutureSee More Headlines Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CUSIPN/A CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,590,000.00 Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMs. Lisa McGrathChief People OfficerMs. Shannon Rourke DevensSr. VP of Devel. OperationsKey CompetitorsOcuphire PharmaNASDAQ:OCUPLianBioNASDAQ:LIANEvaxion Biotech A/SNASDAQ:EVAXFibroGenNASDAQ:FGENKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInsidersJessica FeesSold 9,434 sharesTotal: $8,867.96 ($0.94/share)Robert W RossSold 16,713 sharesTotal: $15,710.22 ($0.94/share)Chandra AdamsSold 3,901 sharesTotal: $3,666.94 ($0.94/share) SURF Stock Analysis - Frequently Asked Questions Should I buy or sell Surface Oncology stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares. View SURF analyst ratings or view top-rated stocks. How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The business earned $0.39 million during the quarter. What is Jeff Goater's approval rating as Surface Oncology's CEO? 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA). When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO. This page (NASDAQ:SURF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsAutomatic Income (from home)Awesomely, LLCBiden Nomination CANCELED?The Freeport SocietyThe A.I. story nobody is telling you (Read ASAP)TradeSmithWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.